Eli Lilly And Company
Mar 13, 2012 at 10:30 | Source: Moneycontrol.com
Jan 31, 2012 at 13:45 | Source: CNBC-TV18
Jul 14, 2011 at 11:37 | Source: PTI
Jun 01, 2011 at 15:59 | Source: CNBC-TV18
Nov 10, 2010 at 08:51 | Source: Reuters
Sep 09, 2010 at 15:51 | Source: CNBC-TV18
.jpg)
Related News »
The Fund will focus primarily on early stage drug development and life sciences company opportunities. The investment by Teralys Capital, together with investments by Eli Lilly and Company (NYSE:LLY; “Lilly”) and other partners, enables a ...
May 29, 2012 at 08:21 | Source: Private Equity Hub
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto™, which combines the DPP-4 inhibitor ...
May 28, 2012 at 05:37 | Source: News-Medical.Net
Eli Lilly and Company - Product Pipeline Review - 2012 - Our pharmaceuticals report, Eli Lilly and Company - Product Pipeline Review - 2012 provides data on the Eli Lilly and Company's research and development focus. The report includes information on ...
May 17, 2012 at 12:24 | Source: Transworld News
INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012 ...
May 28, 2012 at 16:21 | Source: Yahoo Finance
Eli Lilly and Company (LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study. Dulaglutide is a glucagon-like peptide 1 (GLP-1 ...
May 23, 2012 at 22:32 | Source: Yahoo Finance
(Reuters) - Drugmaker Eli Lilly and Co's experimental drug to treat type ... nausea and vomiting, the company said. Lilly added that a dosage of 1.5 mg dulaglutide showed statistically significant reductions in mean 24-hour systolic blood ...
May 22, 2012 at 13:58 | Source: Chicago Tribune
New York -- Eli Lilly and Company (NYSE: LLY) today announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non ...
May 22, 2012 at 15:17 | Source: Inside Indiana Business
Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in ...
May 24, 2012 at 12:59 | Source: StreetInsider.com
(RTTNews.com) - Eli Lilly and Co. (LLY) said that the new Phase 3 data for Tradjenta (linagliptin) tablets in black or African American patients with type 2 diabetes showed significant improvement in blood sugar. According to the company ...
May 24, 2012 at 11:18 | Source: NASDAQ
In 2010 revenue grew by 5.68% compared to 2009. In 2012, however, I predict that the company will record 6.74% lower revenue than in 2011, and modest 2.34% recovery in 2013. I predict 3% growth for the next 4 years. Coming down to the cost side I predict ...
May 16, 2012 at 04:11 | Source: Seekingalpha.com